A Multicenter, Open-label Extension, Multiple Dose, Parallel Group Study To Investigate The Long-term Safety And Tolerability Of Aab-003 (Pf-05236812) Administered Intravenously In Subjects With Mild To Moderate Alzheimer's Disease Previously Treated With Aab-003 Or Placebo In Protocol B2601001
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2014
Price : $35 *
At a glance
- Drugs AAB 003 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 28 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Mar 2014 Planned End Date changed from 1 Oct 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 12 Jan 2014 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov record.